The SME instrument supports top class innovators, entrepreneurs and small companies with funding opportunities and acceleration services. Its main focus is market-creating innovations that shape new markets and generate jobs, growth and higher standards of living.
Grant writing is a challenging area and there is no guarantee of success. Ceratium have supported grant proposals in Horizon 2020 (previously FP7), Innovate UK and DECC funding calls where success rates are often below 20% and sometimes below 10%. Recently in Horizon 2020 we have seen success rates below 5%. We do not win every time, but our results speak for themselves. Since 2010 we have helped business and academic clients secure over €65M of grant funding.
Ceratium have had three success stories with the Department of Architecture and Civil Engineering at the University of Bath provided grant funding of €8.39M for two Eco innovation projects and a Framework Programme 7 integrated project. Our role included helping to shape the project and impact strategies, co-writing the proposal and developing management, implementation and exploitation plans.
Vamorolone is an anti-inflammatory drug being developed by SME ReveraGen Biopharma. This unique and innovative drug development programme has used a Venture Philanthropy funding model with patient groups and grants from the US and Europe. The ambition is to deliver a safe, effective drug for the treatment of Duchenne Muscular Dystrophy to halt the progress of the disease and increase muscle strength.
Ceratium have helped clients win €4M of European FP7 grant funding to deliver the ODAK project. This research project to undertake the pharmaceutical development of an orphan drug for the rare infectious eye disease Acanthamoeba Keratitis which predominantly affects contact lens wearers and can result in blindness. The Ceratium team supported the project management, dissemination and exploitation activities as a consortium partner. The ODAK project started in December 2012, and has successfully completed a range of preclinical studies, a Phase I clinical study in humans and a Phase III clinical study in AK patients is now underway.